Hepatic alterations in experimental metabolic syndrome: metformin and naringin reversion

RIZZI MA; MAZO TM; TOLOSA DE TALAMONI N; RODRÍGUEZ V

Mar del Plata

Congreso; Reunión Anual de Sociedades de Biociencia; 2023

SAIC

Fructose-rich diets (FRD) are responsible for an increase in obesity and metabolic syndrome (MS) cases, many of which may develop into non-alcoholic fatty liver disease (NAFLD). Metformin (Met) is used for the treatment of insulin resistance associated with MS but some clinical studies showed little effect of Met on the histological characteristics of the liver. Naringin (NAR) is a flavonoid with antioxidant, antiapoptotic, and anti-inflammatory properties. Our purpose was to evaluate the effect of co-administration of Met+NAR on systemic and metabolic alterations leading to NAFLD in animals with MS. Male Wistar rats were divided in 5 groups: 1) controls (C); 2) FRD 10% (w/v) in drinking water, 60 days; 3) FRD+Met (100 mg/kg b.w.); 4) FRD+NAR (40 mg/kg b.w.); 5) FRD+Met+NAR. Treatments started on day 21 of FRD administration. Biometric, serum biochemical and liver structure parameters were measured. Fatty acid (FA) profile and gene expression of acetyl COA carboxylase (ACAC) and stearoyl-CoA desaturase 1 (SCD1) were determined in the liver. ANOVA/Bonferroni (p